Invasive group A streptococcal disease: Management and chemoprophylaxis

Paediatrics and Child Health

Volumn 15, Issue 5, 2010, Pages 295-302

  Allen, Upton D ^a   Moore, Dorothy L ^d   Bortolussi, Robert ^b   Finlay, Jane ^c   McDonald, Jane C ^d   Onyett, Heather ^e   Robinson, Joan L ^c   Rousseau Harsany, Élisabeth ^f   Hui, Charles P S ^g   Le Saux, Nicole ^g   Pickering, Larry ^c   Salvadori, Marina I ^h   Kellner, James ^c   MacDonald, Noni E ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c Montreal Children's Hospital ^*

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e KINGSTON GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF MONTREAL   (Canada)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

Chemoprophylaxis; Group A streptococcus; Necrotizing fasciitis; Toxic shock

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFADROXIL; CEFALEXIN; CEFRADINE; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; IMMUNOGLOBULIN; PENICILLIN G;

ANTIMICROBIAL THERAPY; BACTEREMIA; CHEMOPROPHYLAXIS; GANGRENE; GROUP A STREPTOCOCCAL INFECTION; HEALTH CARE; HUMAN; INCIDENCE; INFECTION CONTROL; LABORATORY TEST; MENINGITIS; MYOSITIS; NECROTIZING FASCIITIS; PNEUMONIA; REVIEW; TOXIC SHOCK SYNDROME;

EID: 77954783692     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/15.5.295     Document Type: Review

References (22)

1. Public Health Agency of Canada. Guidelines for the prevention and control of invasive group A streptococcal disease. CCDR 2006;32S2:1-26.
2. Health Canada. Notifiable diseases annual summary: 2001. CCDR 2004;30S3:92-4.
3. Eneli I, Davies HD. Epidemiology and outcome of necrotizing fasciitis in children: An active surveillance study of the Canadian Paediatric Surveillance Program. J Pediatr 2007;151:79-84.
4. American Academy of Pediatrics. Group A streptococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book 2009: Report of the Committee on Infectious Diseases, 28th edn. Elk Grove Village: American Academy of Pediatrics, 2009:616-28.
5. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996;335:547-54.
6. Robinson KA, Rothrock G, Phan Q, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Risk for severe group A streptococcal disease among patients' household contacts. Emerg Infect Dis 2003;9:443-7.
7. Centers for Disease Control and Prevention. Outbreak of invasive group A streptococcus associated with varicella in a childcare center - Boston, Massachusetts, 1997. MMWR 1997;46;944-8.
8. Daneman N, Green KA, Low DE, et al; Ontario Group A Streptococcal Study Group. Surveillance for hospital outbreaks of invasive group A streptococcal infections in Ontario, Canada, 1992 to 2000. Ann Intern Med 2007;147:234-41.
9. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: Recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002;35:950-9.
10. Health Protection Agency, Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. Commun Dis Public Health 2004;7:354-61.
11. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004;113:866-82.
12. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004;38:1526-34.
13. Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis 2003;37:341-3.
14. Darenberg J, Ihendyane N, Sjölin J, et al; Streptlg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
15. Beall B, Gherardi G, Lovgren M, Facklam RR, Forwick BA, Tyrrell GJ. emm and sof gene sequence variation in relation to serological typing of opacity-factor-positive group A streptococci. Microbiology 2000;146:1195-209.
16. Beall B, Facklam RR, Elliott JA, et al. Streptococcal emm types associated with T-agglutination types and the use of conserved emm gene restriction fragment patterns for subtyping of group A streptococci. J Med Microbiol 1998;47:893-8. (Pubitemid 28484381)
17. Facklam RF, Martin DR, Lovgren M, et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types for clinical isolates: emm103 to emm124. Clin Infect Dis 2002;34:28-38. (Pubitemid 33152662)
18. Facklam R, Beall B, Efstratiou A, et al. emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis 1999;5:247-53.
19. Tyrrell GJ, Lovgren M, Forwick B, Hoe NP, Musser JM, Talbot JA. M types of group A streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999. J Clin Microbiol 2002;40:4466-71.
20. Health Canada. Routine practices and additional precautions for preventing the transmission of infection in health care. Revision of isolation and precaution techniques. CCDR 1999;25S4:1-142. 〈www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/99vol25/25s4/index.html〉 (Accessed on March 24, 2010).
21. Health Canada. Prevention and control of occupational infections in health care. CCDR 2002;28S1:1-264. 〈www.phacaspc. gc.ca/publicat/ccdr-rmtc/ 02vol28/28s1/index.html〉 (Accessed on March 24, 2010).
22. Health Canada. Hand washing, cleaning, disinfection and sterilization in health care. CCDR 1998;24S8:1-55. 〈www.phac-aspc.gc.ca/publicat/ccdr-rmtc/ 98pdf/cdr24s8e.pdf〉 (Accessed on March 24, 2010).